Construction method of nano-drug carrier based on nucleic acid

Abstract

The invention discloses a construction method of a nano-drug carrier based on nucleic acid. The drug carrier is of a columnar rigid structure that six groups of double helixes are mutually twisted; acolumnar going-through hole, which is 1.8-2nm in diameter, is formed in the middle of the columnar rigid structure; two ends of the carrier are blocked by locked nucleic acid single strands lock1 andlock3; one part of a blocking sequence lock3 at one end is a complementary sequence of a target aptamer mRNA; measured by dynamic light scattering, the overall length of the carrier is 40+ / -4.3nm; when the target aptamer mRNA exists in cells, an entropy substitution process occurs since the number of paired bases between the target mRNA and the lock3 is much greater than a binding number between the lock3 and basic structural ports of the carrier, so that one end of the carrier is opened, and drugs in the carrier are released. According to the construction method provided by the invention, bytaking the nucleic acid existing in an organism as a raw material, a pairing situation between the bases can be regulated and controlled through artificial design, so that the nucleic acid is converted into a shape-controllable origami structure through three-dimensional folding, and the basic carrier for drug loading is obtained.

Description

technical field [0001] The invention relates to a construction method of a nucleic acid-based nano drug carrier. Background technique [0002] As an important nanomaterial, nanocarriers have broad application prospects in the field of biomedicine due to their excellent penetration and delivery properties and controlled drug release capabilities. One of the most important directions is anti-tumor targeted sustained-release drugs. development. [0003] The drug delivery system is designed to solve the problem of drug targeting. Many chemical drugs achieve good therapeutic effects in vitro, but they are not effective in the human body. The reason is that these drugs lack targeting and lack of in vivo environment. Stability requires the development of special drug delivery technologies to overcome problems such as low solubility, in vivo instability, low bioavailability and potential biological toxicity to normal tissues. A good drug delivery system is the key to solving the pr...

AI Technical Summary

Problems solved by technology

[0011] The technical problem to be solved by the present invention is to provide a new nano-medicine carrier platform by using the nucleic acid with good biocompatibility existing in large quantities in organisms as a material, and through the origami structure of DNA. The advantages of good affinity for conventional liposome encapsulation, as well as the stability of the slow release of the copolymer structure and the targeting of aptamer recognition, at the same time solve the lack of targeting of liposomes, the biological safety of the copolymer and the adaptability The problem of the single role of body recognition

Images